Voices

Aug 28, 2025, 06:54

Paolo Bossi: Advancing Cancer Prevention with the Aphrodite Trial on OPMD

Paolo Bossi, Head of the Head and Neck Medical Oncology Unit and Associate Professor of Medical Oncology at Humanitas University and Humanitas Cancer Center, shared a post on LinkedIn:

“Grateful to Cancer Research Institute supporting the Aphrodite trial: CD40 agonist to intercept malignant transformation of Oral Potentially Malignant Disorders (OPMD). The trial and its translational correlates will shed light on a new way to reduce the risk of oral cavity cancer.

Humanitas Cancer Center and Humanitas University are the coordinators of the Aphrodite trial.”

Read further.

More posts featuring Paolo Bossi on OncoDaily.

Aphrodite Aphrodite trial cancer Cancer Research Institute CRI Humanitas University and Humanitas Cancer Center OncoDaily Oncology OPMD Oral Potentially Malignant Disorders Paolo Bossi

100 Influential Women in Oncology: Key Opinion Leaders to Follow on Social Media in 2025

China Approved DATROWAY (Datopotamab Deruxtecan) for HR-Positive, HER2-Negative Metastatic Breast Cancer

Simon Mooijaart: Patient Perspectives on Antithrombotic Therapy in Advanced Cancer

Hidden Risks: BRCA Mutations and Breast Implants - CancerWorld

Neil Ranasinghe: What’s the Difference Between a Clinician and a Technical Author?